Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer
Public ClinicalTrials.gov record NCT00038467. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized Double-Blind Trial In Postmenopausal Women With Primary Breast Cancer Who Have Received Adjuvant Tamoxifen For 2-3 Years, Comparing Subsequent Adjuvant Exemestane Treatment With Further Tamoxifen
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To compare the sequential administration of exemestane with administration of further tamoxifen until 5 years in postmenopausal women with operable breast cancer who have already received 2-3 years of adjuvant tamoxifen, in terms of disease-free survival (DFS), overall survival (OS), incidence of contralateral breast cancer and long-term tolerability.
Study identification
- NCT ID
- NCT00038467
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 4,740 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 30 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 1998
- Primary completion
- May 31, 2003
- Completion
- Feb 28, 2013
- Last update posted
- May 6, 2014
1998 – 2013
United States locations
- U.S. sites
- 57
- U.S. states
- 11
- U.S. cities
- 39
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Birmingham | Alabama | 35205 | — |
| Pfizer Investigational Site | Birmingham | Alabama | 35213 | — |
| Pfizer Investigational Site | Birmingham | Alabama | 35235 | — |
| Pfizer Investigational Site | Green Valley | Arizona | 85614 | — |
| Pfizer Investigational Site | Green Velley | Arizona | 85614 | — |
| Pfizer Investigational Site | Tucson | Arizona | 85704 | — |
| Pfizer Investigational Site | Tucson | Arizona | 85710 | — |
| Pfizer Investigational Site | Tucson | Arizona | 85712 | — |
| Pfizer Investigational Site | Tucson | Arizona | 85715 | — |
| Pfizer Investigational Site | Tucson | Arizona | 85745 | — |
| Pfizer Investigational Site | Boulder | Colorado | 80304 | — |
| Pfizer Investigational Site | Colorado Springs | Colorado | 80909 | — |
| Pfizer Investigational Site | Denver | Colorado | 80218 | — |
| Pfizer Investigational Site | Fort Collins | Colorado | 80528 | — |
| Pfizer Investigational Site | Lakewood | Colorado | 80228 | — |
| Pfizer Investigational Site | Thornton | Colorado | 80260 | — |
| Pfizer Investigational Site | Jacksonville | Florida | 32204 | — |
| Pfizer Investigational Site | Jacksonville | Florida | 32207 | — |
| Pfizer Investigational Site | Jacksonville Beach | Florida | 32250 | — |
| Pfizer Investigational Site | Ocala | Florida | 34474 | — |
| Pfizer Investigational Site | Orange Park | Florida | 32073 | — |
| Pfizer Investigational Site | Fishers | Indiana | 46037 | — |
| Pfizer Investigational Site | Fishers | Indiana | 46038 | — |
| Pfizer Investigational Site | Indianapolis | Indiana | 46219 | — |
| Pfizer Investigational Site | Indianapolis | Indiana | 46227 | — |
| Pfizer Investigational Site | Indianapolis | Indiana | IN 46219 | — |
| Pfizer Investigational Site | Cedar Rapids | Iowa | 52403 | — |
| Pfizer Investigational Site | Pittsfield | Massachusetts | 01201 | — |
| Pfizer Investigational Site | Albany | New York | 12206 | — |
| Pfizer Investigational Site | Latham | New York | 12110-0610 | — |
| Pfizer Investigational Site | Portland | Oregon | 97225 | — |
| Pfizer Investigational Site | Portland | Oregon | 97227 | — |
| Pfizer Investigational Site | Arlington | Texas | 76014-2084 | — |
| Pfizer Investigational Site | Bedford | Texas | 76022 | — |
| Pfizer Investigational Site | Dallas | Texas | 75230-2510 | — |
| Pfizer Investigational Site | Dallas | Texas | 75231 | — |
| Pfizer Investigational Site | Dallas | Texas | 75246 | — |
| Pfizer Investigational Site | El Paso | Texas | 79902 | — |
| Pfizer Investigational Site | El Paso | Texas | 79915 | — |
| Pfizer Investigational Site | Garland | Texas | 75042 | — |
| Pfizer Investigational Site | Houston | Texas | 77024 | — |
| Pfizer Investigational Site | Houston | Texas | 77029 | — |
| Pfizer Investigational Site | Houston | Texas | 77030 | — |
| Pfizer Investigational Site | Houston | Texas | 77074 | — |
| Pfizer Investigational Site | Longview | Texas | 75601 | — |
| Pfizer Investigational Site | McAllen | Texas | 78503 | — |
| Pfizer Investigational Site | Mesquite | Texas | 75150 | — |
| Pfizer Investigational Site | Odessa | Texas | 79761 | — |
| Pfizer Investigational Site | Pasadena | Texas | 77502 | — |
| Pfizer Investigational Site | Plano | Texas | 75075-7787 | — |
| Pfizer Investigational Site | San Antonio | Texas | 78217 | — |
| Pfizer Investigational Site | Sherman | Texas | 75090 | — |
| Pfizer Investigational Site | Sugar Land | Texas | 77479 | — |
| Pfizer Investigational Site | Tyler | Texas | 75702 | — |
| Pfizer Investigational Site | Weslaco | Texas | 78596 | — |
| Pfizer Investigational Site | Spokane | Washington | 99202 | — |
| Pfizer Investigational Site | Spokane | Washington | 99218 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 320 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00038467, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 6, 2014 · Synced Sep 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00038467 live on ClinicalTrials.gov.